Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lyell Immunopharma, Inc.

12.80
+4.8160.19%
Volume:1.27M
Turnover:14.40M
Market Cap:189.53M
PE:-0.52
High:13.18
Open:8.01
Low:7.78
Close:7.99
Loading ...

Lyell Immunopharma trading resumes

TIPRANKS
·
02 Jun

Lyell Immunopharma trading halted, news pending

TIPRANKS
·
31 May

Lyell Immunopharma Inc - Announces 1-for-20 Reverse Stock Split - SEC Filing

THOMSON REUTERS
·
29 May

Lyell Immunopharma Announces 1-for-20 Reverse Stock Split Effective May 30, 2025

Reuters
·
29 May

Lyell Immunopharma Stockholders Approve Key Proposals

TIPRANKS
·
22 May

Lyell Immunopharma Inc. Conducted Annual Stockholders Meeting

Reuters
·
22 May

Morgan Stanley Keeps Their Hold Rating on Lyell Immunopharma (LYEL)

TIPRANKS
·
19 May

Lyell Immunopharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

Lyell Immunopharma Q1 EPS $(0.18) Beats $(0.20) Estimate, Sales $7.00K Up From $3.00K YoY

Benzinga
·
14 May

BRIEF-Lyell Immunopharma Q1 Net Income USD -52.195 Million

Reuters
·
14 May

Lyell Immunopharma Inc. Reports Decreased Net Loss of $52.2 Million in Q1 2025, Driven by Absence of Prior Year Impairment Expenses

Reuters
·
14 May

Lyell Immunopharma Inc expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
02 May

Lyell Immunopharma Announces Oral Presentation of New Clinical Data From the Phase 1/2 Trial of Lyl314 for the Treatment of Large B-Cell Lymphoma at the International Conference on Malignant Lymphoma (Icml) 2025

THOMSON REUTERS
·
01 May

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

GlobeNewswire
·
01 May

Cautious Hold Rating on Lyell Immunopharma Amid Promising Developments and Competitive Challenges

TIPRANKS
·
16 Apr

Lyell Immunopharma Says its Relapsed Large B-Cell Lymphoma Therapy Receives US FDA's REMAT Designation

MT Newswires Live
·
15 Apr

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (Rmat) Designation for Lyl314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

THOMSON REUTERS
·
15 Apr

Director’s Bold Move: Major Stock Purchase in Lyell Immunopharma!

TIPRANKS
·
03 Apr

Lyell Immunopharma to Cut Jobs, Close West Hills Plant

Dow Jones
·
02 Apr

BRIEF-Lyell Immunopharma Inc - To Close West Hills Manufacturing Facility - SEC Filing

Reuters
·
02 Apr